0001658247false00016582472026-06-182026-06-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________
FORM 8-K
_________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | |
Date of Report (Date of earliest event reported): June 18, 2026 |
_________________________________________________________
Crinetics Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
_________________________________________________________
| | | | | | | | |
| Delaware | 001-38583 | 26-3744114 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
| | |
| 6055 Lusk Boulevard | | |
San Diego, California | | 92121 |
| (Address of Principal Executive Offices) | | (Zip Code) |
| | |
Registrant’s Telephone Number, Including Area Code: (858) 450-6464 |
(Former Name or Former Address, if Changed Since Last Report)
_________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading
Symbol(s) | | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | | CRNX | | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07 Submission of Matters to a Vote of Security Holders.
The annual meeting of stockholders of Crinetics Pharmaceuticals, Inc. (the “Company”) was held online via live audio webcast on June 18, 2026 (the “Annual Meeting”). At the Annual Meeting, there were present, virtually or by proxy, holders of 102,030,415 shares of common stock, or approximately 97% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting are as follows:
Proposal One - Election of Directors
The Company’s stockholders approved the election of three Class II directors to the Board of Directors for three-year terms to expire at the 2029 annual meeting of stockholders. The results of such vote were:
| | | | | | | | | | | | | | | | | |
| Votes For | | Votes Withheld | | Broker Non-Votes |
| Caren Deardorf | 73,454,076 | | 23,532,328 | | 5,044,011 |
| Weston Nichols, Ph.D. | 90,208,564 | | 6,777,840 | | 5,044,011 |
| Stephanie S. Okey, M.S. | 72,225,313 | | 24,761,091 | | 5,044,011 |
Proposal Two - Ratification of Selection of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were:
| | | | | | | | | | | | | | | | | |
| Votes For | | Votes Against | | Abstentions | |
| 101,675,974 | | 341,727 | | 12,714 | |
Proposal Three - Approval, on an advisory basis, of the compensation of the Company’s named executive officers
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were:
| | | | | | | | | | | | | | | | | | | | |
| Votes For | | Votes Against | | Abstentions | | Broker Non-Votes |
| 91,657,992 | | 2,698,538 | | 2,629,874 | | 5,044,011 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | | | | |
| | | Crinetics Pharmaceuticals, Inc. |
| | | |
| Date: | June 22, 2026 | By: | /s/ R. Scott Struthers, Ph.D. |
| | | R. Scott Struthers, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer) |
